11.45
-0.43%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Youcare Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 688658.SS. It has been listed since 24 December 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.45bn and a net loss of CN¥253.8m. At that date it held total assets of CN¥5.21bn and shareholders' equity of CN¥3.32bn.
Youcare Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of chemical raw materials, chemical drugs, and biological drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-24. The Company’s products are mainly cardiovascular and cerebrovascular drugs, digestive system drugs, diabetes drugs and anti-infective drugs, including ginkgo biloba extract injection, gastrodin injection, lansoprazole for injection, and omeprazole enteric-coated capsules , metformin hydrochloride sustained-release tablets, cefuroxime sodium for injection and ceftriaxone sodium for injection, etc. The firm conducts its businesses within the China market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Dec 2020
- Employees
- 3,188
- Website
- youcareyk.com ↗
Leadership
Pay as last reported
- Mr. Weishi YuChairman of the Board, since 2001CN¥1.3m
- Ms. Yan LiuChief Financial OfficerCN¥907,800
- Mr. Fei YuGeneral Manager, Director, since 2019CN¥1.1m
- Mr. Jiang ZhangDeputy General Manager, Director, since 2019CN¥1.1m
- Mr. Gengshen SongDeputy General ManagerCN¥1.1m
- Mr. Lei YangDeputy General Manager of Research and Development
- Mr. Wei ZhangDeputy General ManagerCN¥1.1m
- Mr. Mengyang HaoSecretary of the Board
- Mr. Zhikuan GuanDirector
- Mr. Pengfei YuDirectorCN¥604,500
- Mr. Qibo ZhangDirectorCN¥1.1m
- Mr. Keji ChenIndependent DirectorCN¥200,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Beijing with 3,188 employees
- Offers a diverse product portfolio including cardiovascular, cerebrovascular, digestive system, diabetes, and anti-infective drugs
- Conducts business both within China and overseas markets
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market share provided
- No information on competitive advantages or unique technologies
Opportunities
- Expansion into international markets beyond current overseas presence
- Growth potential in the pharmaceutical sector within China
- Potential for R&D advancements in chemical and biological drugs
Threats
- No specific threats mentioned in the provided information
- No data on regulatory challenges or market competition
- No information on potential risks in the pharmaceutical industry
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.